Canget biotekpharma, llc

Canget biotekpharma, llc 审查

评论 9
3.8
评论 9
过滤器:
评分
语言
种类:
最近的
G
7 几个月前

I recently purchased from Canget biotekpharma, llc...

I recently purchased from Canget biotekpharma, llc and I am extremely satisfied with the products. The quality is excellent and the customer service is outstanding. I would highly recommend them.

L
8 几个月前

I highly recommend Canget biotekpharma, llc. The p...

I highly recommend Canget biotekpharma, llc. The products are great and the customer service is outstanding. They always respond promptly and go above and beyond to ensure customer satisfaction.

B
12 几个月前

The service provided by this company was excellent...

The service provided by this company was excellent. The quality of the products was top-notch and the customer support was exceptional. I would definitely purchase from them again.

Y
1年以前

I had a great experience with Canget biotekpharma,...

I had a great experience with Canget biotekpharma, llc. The staff was very knowledgeable and helpful. They took the time to answer all of my questions and made sure I understood everything. I would definitely recommend them to others.

J
1年以前

👌 I had a wonderful experience with Canget biotekp...

👌 I had a wonderful experience with Canget biotekpharma, llc. The products are of great quality and the customer service is fantastic. I would highly recommend them to anyone in need of their products.

V
1年以前

I recently purchased products from this company an...

I recently purchased products from this company and I'm very happy with my decision. The quality of the products is superb and the customer service is top-notch. I would definitely buy from them again.

关于Canget biotekpharma, llc

Canget BioTekpharma, LLC:用新型抗癌药物革新癌症治疗

癌症是影响全世界数百万人的最具破坏性的疾病之一。尽管癌症研究和治疗取得了重大进展,但要找到治愈这种致命疾病的方法还有很长的路要走。然而,Canget BioTekpharma, LLC 是一家生物技术和生物制药公司,旨在通过开发新型抗癌药物来改变癌症治疗的格局。

Canget BioTekpharma 由 Fengzhi Li 博士创立,是从位于纽约布法罗的 Roswell Park 癌症研究所 (RPCI) 分拆出来的。该公司的主要重点是开发针对癌细胞同时保护健康细胞的创新疗法。

Canget BioTekpharma 的团队由经验丰富的科学家和研究人员组成,他们致力于发现有效治疗癌症的新方法。他们使用尖端技术和最先进的设施开发具有彻底改变癌症治疗潜力的新型抗癌药物。

该公司的研究工作集中在使用高通量筛选 (HTS)、虚拟筛选 (VS) 和基于结构的药物设计 (SBDD) 等先进筛选技术确定药物开发的新靶点。这些方法使他们能够识别对癌细胞具有高度特异性的化合物,同时最大限度地减少对正常细胞的毒性。

Canget BioTekpharma 在其管道中有几个有前途的候选药物,用于治疗各种类型的癌症,如乳腺癌、肺癌、前列腺癌、卵巢癌、胰腺癌等。其中一个候选药物是 CBP-307,它在针对三阴性乳腺癌 (TNBC) 的临床前研究中显示出可喜的结果。

除了开发新型抗癌药物外,Canget BioTekpharma 还与全球其他公司和学术机构合作开展与肿瘤学相关的各种研究项目。这种合作使他们能够获得多样化的专业知识和资源,从而加速他们的药物发现过程。

除了开发创新癌症疗法的核心使命外,Canget BioTekpharma 还致力于确保其产品可供全球患者使用。该公司在全球开展业务,并与监管机构密切合作,以确保其产品符合最高的安全性和有效性标准。

总之,Canget BioTekpharma 是一家处于开发新型抗癌药物前沿的生物技术和生物制药公司。其经验丰富的科学家和研究人员团队使用尖端技术来确定药物开发的新目标,同时最大限度地减少对正常细胞的毒性。 Canget BioTekpharma 拥有几个有前途的候选药物,有可能彻底改变癌症治疗并改善全球患者的治疗效果。

已翻译
Canget biotekpharma, llc

Canget biotekpharma, llc

3.8